CyTOF and O-Link Assessment in the NCI COVID-19 in Cancer Patients Study(NCCAPS)

Awarded Limited / Sole Source Justification Posted

Solicitation number
75N91021C00003-4
Agency
Set-aside
No set-aside

Opportunity facts

Contract number
75N91021C00003 Federal contract award
Place of performance
United States

Notice details come from SAM.gov. Updated .

About this opportunity

This Limited/Sole Source Justification Notice from the National Cancer Institute within the National Institutes of Health and Department of Health and Human Services extends a sole source contract by 12 months to an unknown vendor for CyTOF and O-Link assessment services in support of the NCI COVID-19 in Cancer Patients Study. The justification modifies the period of performance to continue analyzing immune responses and protein biomarkers in cancer patients infected with COVID-19 through CyTOF and O-Link assessment. No additional award values or timelines are specified in the redacted justification.

Notice text

The purpose of this modification is to extend the Period of Performance by 12 months. This notice is to provide a redacted version of the Justification for Other Than Full and Open Competition

Awarded contract 75N91021C00003 to unknown vendor for unknown amount on 2022-12-20.

Files

Notice history

Notice Type Posted
This notice Latest Limited / Sole Source Justification
CyTOF and O-Link Assessment in the NCI COVID-19 in Cancer Patients Study(NCCAPS) Latest pre-solicitation Pre-Solicitation
CyTOF and O-Link Assessment in the NCI COVID-19 in Cancer Patients Study(NCCAPS) Limited / Sole Source Justification
CyTOF and O-Link Assessment in the NCI COVID-19 in Cancer Patients Study(NCCAPS) Original Pre-Solicitation

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors